Strong Revenue Growth
OrthoPediatrics reported a global revenue growth of 17% in Q1 2025, driven by trauma, scoliosis, and OPSB segments. U.S. revenue increased by 19%, contributing 78% of the total revenue.
Increased Profitability
The company reduced its adjusted EBITDA loss by more than half year-over-year and improved free cash flow by 36%. Gross profit margin increased to 73% from 72% in the previous year.
Successful Product Approvals
Five FDA approvals were received, including the Verteglide system and 3P pediatric plating platform HIP system, enhancing the product portfolio.
Scoliosis Segment Growth
Scoliosis global revenue increased by 34%, driven by the adoption of Response, Apifix, and 7D technology. New approvals like Verteglide are expected to further enhance growth.
OPSB Clinic Expansion
The OPSB segment showed a growth of over 20% with successful expansion into new territories such as North Carolina, with plans for further expansion.
Positive Future Outlook
The company increased its full-year revenue guidance to $236 million to $242 million, reflecting a growth of 15% to 18%.